cbdMD initiated this process in March 2021, with the submission of a comprehensive dossier detailing the ingredient's identity, quality, stability, hemp sourcing, extraction controls, labeling, testing requirements, usage instructions, and extensive safety data. In February 2022, cbdMD became the first U.S. brand to receive dossier validation. Since then, cbdMD has worked closely with the FSA, actively addressing inquiries to expedite the regulatory review process.